Pharma Business - March 13, 2017
Idogen strengthens its position in the US
Idogen announces that the United States Patent & Trademark Office has issued a “Notice of Allowance”, which means that it intends to grant Idogen’s patent application. The United States Patent & Trademark Office (USPTO) has communicated its intention to grant Idogen’s Patent Application No. 14/553,098. The patent belongs to Idogen’s second patent family and covers […]
Intellectual Property - February 8, 2017
Idogen reaches formal granting of patent in Japan
Idogen has announced that the Japan Patent Office (“JPO”) has granted the company’s patent application. The patent provides Idogen’s vaccine technology with a broad protection and further strengthens the company’s patent portfolio in an important market. The Japan Patent Office has now formally granted Idogen’s Patent Application covering induction of IDO for treatment of autoimmune […]
Intellectual Property - January 13, 2017
The EPO intends to grant Idogen’s patent application
Idogen announces that the European Patent Office (EPO) has issued a Notice of Intention to Grant, which means that the patent office intends to grant Idogen’s patent application, covering the company’s tolerogenic vaccine technology. A related patent application received a Notice of Allowance in Japan in December 2016. The patent, and its validation in key […]
Biotech Business - June 22, 2016
Idogen collaborates with the University of Oxford
Idogen has initiated a collaboration with Richard Williams’ research group at the Kennedy Institute of Rheumatology at the University of Oxford. Using a research model of rheumatoid arthritis, the collaboration will investigate the treatment effect of follow-up molecules to Zebularine, which Idogen identified and filed for patent protection for this Spring. The company announced in April 2016 that […]
